50-100). The sites of brainstem metastases included the pons (21 tumors) and midbrain (six tumors). Other brain metastases were present in 14 patients (34 other tumors). Among the 26 patients, the primary malignancy was lung cancer in 10 (six adenocarcinoma, three squamous cell carcinoma, and one small cell carcinoma), renal cell carcinoma in five, melanoma in four, breast cancer in three, squamous cell carcinoma in three (one larynx, two skin), and lymphoma in one.
Twenty patients presented with brainstem signs. The most common sign was hemiparesis, followed by cranial nerve paralysis and ataxia (Table 2) . Histological confirmation was not obtained in 21 patients because all of them had known systemic cancer; in this context, the appearance of clinical symptoms and a contrast-enhancing mass lesion was considered diagnostic. Stereotactically guided biopsy sampling was performed when imaging features were atypical or the diagnosis of primary malignancy was remote (five patients in this series). 20 The median time between the diagnosis of the primary tumor and the diagnosis of brain involvement was 24 months (range 0-132 months). All patients with newly diagnosed metastatic disease received fractionated WBRT: 15 patients underwent radiosurgery immediately after radiotherapy and in four radiosurgery was performed 1 to 9 months later. The median total WBRT dosage was 30 Gy (range 23.4-44 Gy) administered with standard fractionation (1.8-3 Gy) delivered in daily treatment over 2 to 5 weeks. Five patients who received WBRT more than 3 months before radiosurgery also received an additional dose of 10 Gy (in four fractions either to the whole-brain field or to the local tumor radiation field) immediately before or after radiosurgery. Nine patients presented with ac- tive extracranial systemic disease. Eight received chemotherapy (five before and three after radiosurgery) and four underwent immunotherapy.
Radiosurgery Technique
In all 26 patients the Leksell stereotactic coordinate frame (Model G; Elekta Instruments, Atlanta, GA) was applied after the patients received a local anesthetic supplemented with mild sedation. High-resolution stereotactic CT scanning with coronal and sagittal reformatted images or stereotactic gadolinium-enhanced MR imaging (using 1-mm slice intervals obtained with a volume acquisition) was performed during radiosurgery for target coordinate determination and dose planning. The 201-source 60 Co gamma knife unit was used for radiosurgery. The radiation volume was determined and shaped to the tumor margin in all 26 patients by using an average of 2.5 isocenters (range 1-7 isocenters). Eleven patients had a solitary brainstem tumor, one had two tumors in the pons, and 14 had brainstem tumors as well as other brain metastases (range one-five). The average maximum tumor diameter was 1.7 cm (range 1-3.6 cm). The median radiosurgical treatment volume was 1.1 ml (range 0.3-9.7 ml), and the median radiosurgical tumor margin dose was 16 Gy (range 12-20 Gy); in most patients the 50% isodose line was selected. Corticosteroid drugs were administered perioperatively in all patients with symptomatic peritumoral edema identified on CT or MR studies. A 40-mg dose of methylprednisolone was administered intravenously immediately after radiosurgery.
Statistical Analysis
Survival data were calculated using the Kaplan-Meier method. Factors affecting survival were assessed using the log-rank test and the Cox proportional-hazards model (Table 1) .
Results

Neuroimaging-Identified Response
The imaging-defined tumor response is presented in Table 1 and Fig. 1 . Of the 26 patients, we did not obtain follow-up images in five because of their short survival times. Four of these patients had active extracranial disease that led to their death. The other 21 patients with 22 brainstem metastases underwent neuroradiological studies at planned 3-month intervals. In these patients, local control had been achieved in 21 (95%) of the 22 tumors at last follow-up review (five had disappeared entirely, 13 had shrunk, and three had no growth). Neuroimaging in one patient (Case 1) demonstrated tumor shrinkage at first but mild enlargement 7 months later. This patient died of systemic disease progression and a new brain tumor 14 months after radiosurgery. Of the 14 patients with 34 other brain metastases, one did not undergo follow-up imaging. In the other 13 patients with 32 nonbrainstem metastases, local control was achieved in 29 (91%); seven tumors disappeared entirely, 15 shrank, and seven had no growth. There were 11 cases of distant cerebral recurrence, and five patients underwent a second gamma knife radiosurgery.
Clinical Response
No patient died or developed a new or progressive neurological deficit from growth of a tumor that was managed with radiosurgery. Ten of 20 patients who had brainstem neurological deficits at the time of radiosurgery had subsequent marked improvement; eight of these remained stable and two deteriorated. In the latter two patients the worsening was attributed to tumor enlargement or tumor persistence. Three of five patients with only nonbrainstem deficits showed improvement. Acute and transient mild complications after radiosurgery were found in four patients who experienced postoperative nausea, vomiting, or dizziness that resolved within hours. Three patients had seizures that were controlled with an anticonvulsant medication. Neuroimaging revealed no evidence of delayed adverse radiation effects in any patient. These are usually characterized by diffuse and patchy peritumoral enhancement together with increased signal on long-relaxationtime MR images.
Survival Rates
Twenty-two patients died 1 to 33 months posttreatment. Four patients were still alive 6, 6, 8, and 14 months after radiosurgery, respectively. The median survival time was 11 months after diagnosis (95% confidence interval 8-14 months) and 9 months after radiosurgery (95% confidence interval 3.7-14.3 months). Figure 2 upper shows a Kaplan-Meier survival curve for this series of 26 patients. The 1-year actuarial survival rate was 21.7% postradiosurgery and 29.9% postdiagnosis. Paradoxically, the median survival time after diagnosis was 7.3 months for patients with brainstem metastases as the only site of brain involvement, and 10 months for patients with multiple metastases (p = 0.38, log-rank test). The mean survival time after diagnosis of the primary malignancy was 46.9 months (range 8-132 months). Eighteen patients died of progression of their systemic disease, three of new tumor growth, and one of systemic disease and new tumor growth. Eight months after radiosurgery one of them suffered a catastrophic intracranial hemorrhage caused by a remote new tumor deposit. Despite surgical evacuation of the hemorrhage, this patient died 11 days later.
To ascertain factors that contributed to survival, various patient characteristics were analyzed using univariate and multivariate testing. Older age (p = 0.008), chemotherapy or immunotherapy (p = 0.003), and active extracranial systemic disease (p = 0.0004) were significant factors in univariate testing. The only significant favorable factor for survival in multivariate analysis was the absence of active extracranial systemic disease (Fig. 2 lower) .
Discussion
Because of their dismal prognosis and relative rarity, little attention has been paid to the management of patients with brainstem metastases. In various clinical studies, the incidence of brainstem metastasis varied from 0.5 to 11%. 5, 6, 8, 14, 16, 22, 31 The frequency of these tumors is disproportionately higher than the relative weight of brainstem to cerebrum (1:50). 2, 16 Most reports were autopsy series in which the investigators had noted no correlation between tumor size and clinical manifestations. Miliary metastases were microscopic, and few were large enough to produce obvious clinically observed dysfunction. Thus, clinical presentation with an intraaxial brainstem metastasis is uncommon.
Brainstem metastases are considered to be quickly lethal in most patients. Hunter and Rewcastle 16 retrospectively followed four patients with asymptomatic brainstem metastases; survival varied from 1 to 6 months. Weiss and Richardson 30 reported on three patients with solitary brainstem metastases who received radiation therapy and high-dose corticosteroid drugs and survived only 1 to 4 months. In contrast, Derby and Guiang 7 reported on one patient with renal cell carcinoma who lived 32 months. This outlook for brainstem metastasis seems more related to the biology of the individual neoplasm than to the management method. Rarely, the neoplasm may demonstrate indolent behavior of the metastasis after ablation of the source. 13 In our series, we did not identify a correlation between the histological tumor type and patient survival.
We found that 5% of patients in our series had symptomatic brainstem tumors. On average, these rates are higher than those of previous reports and are likely due to more aggressive use of neuroradiological screening. Currently, resection is accepted as an important part of the management of selected patients with brain metastases. 4, 27, 29 With improvements in imaging and operative techniques, surgical complication rates have fallen dramatically. However, these benefits have not been translated to the care of patients with brainstem tumors. On the other hand, the potential for stereotactic radiosurgery to be used in brainstem locations offers new hope for patients with these difficult tumors.
Local Tumor Response and Effect on Survival
Because many patients with brainstem metastases die of uncontrolled intracranial disease, local control is the first step to lengthened survival. Surgical resection immediately eliminates the effect of increased intracranial pressure and direct irritation that these tumors cause. 27 Overall, in recent series in which heterogeneous groups of patients were examined, survival times of 10 to 14 months were reported. 4, 10, 27, 29, 31 Local recurrence after surgical resection occurs in 5 to 20%.
In radiosurgical series, the local tumor control rate is also high. Kihlstrom, et al., 18 reported a 94% control rate with a median 7-month patient survival time for multiple metastases and 12 months for those with solitary metasta-sis in 235 treated lesions. Engenhart, et al., 9 also reported a 94% control rate in 102 tumors. Alexander, et al., 1 reported on 248 patients with 421 treated lesions and found an 83% control rate with a median survival time of 9 months.
In our study, the local control rate was 95%. This is comparable with that found in other brain metastasis series (82-95%). 1, 9, 11, 12, 18, 27 The median survival time was 9 months after radiosurgery and 11 months after diagnosis. Compared with our median reported postradiosurgery survival times for patients with melanoma (7 months), 24 renal cell carcinoma (11 months), 23 and lung cancer (10 months), 19 the results for patients with brainstem lesions were not significantly different. Thirteen patients (50%) showed improvement in neurological deficits following radiosurgery. Although not curative, tumor control is important in extending survival time and maintaining or improving quality of life. All of these patients were able to discontinue or taper corticosteroid medications.
The safety of brainstem radiosurgery was related to accurate and conformal radiosurgical targeting and safe dose selection. Brainstem radiosurgery must achieve the desired therapeutic goal of tumor destruction. Thus, only patients with tumors for which an adequate radiation dose can be delivered should be selected to undergo radiosurgery. Although the minimum effective tumor dose is not known, we do not administer less than 11 Gy to the margin of any brainstem tumor. A dose as high as 20 Gy to the tumor margin, which is also received by the brainstem parenchyma, has been safe in our experience, although in current practice we limit the margin dose to 15 Gy. In our early experience, when higher doses were used, 20 Gy delivered to the margin of petrous apex meningiomas (a dose also received by the surface of the brainstem) resulted in adverse radiation effects in two patients. Even though the 20-Gy dose did not cause deficits in our patients with metastasis, we have lowered all radiosurgery doses delivered near or within the brainstem. There may be additional reasons for the safety of brainstem metastasis radiosurgery at these doses. First, the average latency period before parenchymal radiosurgery complications are seen is approximately 9 months, a length of time equal to the median survival time in this series, and thus half of the patients did not live long enough to sustain a complication. Second, most brainstem metastases are small, and this provides a steep falloff in the radiation dose outside the tumor. Lower doses are administered to patients with larger tumors. 28 Although several patients developed nausea or transient dizziness postradiosurgery, radiosurgery in addition to the radiation delivered using fractionated techniques did not result in unacceptable subsequent brainstem or cranial nerve morbidity.
Fractionated Radiotherapy and Adjuvant Systemic Therapy
The relatively good survival times in our group were related not only to radiosurgery but also to the potential benefit provided by adjuvant WBRT (24 cases), systemic chemotherapy (eight cases), and immunotherapy (four cases). The palliative benefit of radiotherapy for brain metastasis was established and recommended for the majority of patients. 15, 25, 26 We used fractionated WBRT to treat local or remote disease that was ill defined even on contrast-enhanced MR imaging. In our series, 90% of our patients received WBRT before or after radiosurgery. More recently, in patients with relatively radioresistant tumors like melanoma or renal cell carcinoma, we have begun to use radiosurgery alone for patients with solitary metastasis. Chemotherapy has been used mostly for protocol-based management of extracranial disease and its effectiveness is difficult to assess. In our series, 46% of our patients received systemic chemotherapy or immunotherapy. Although the role of chemotherapy in the treatment of brain tumors may be limited by blood-brain barrier integrity, systemic disease control should prolong survival.
Increasing numbers of patients with brainstem metastases are being identified. The majority of these patients require active disease management with the goals of tumor control and prolonged life. We believe that stereotactic radiosurgery together with WBRT and systemic management is safe and effective in achieving these goals in patients with brainstem metastases.
